CureVac
Develops drugs that allow the human body to fight various diseases.
Launch date
Employees
Market cap
CAD1.1b
Enterprise valuation
CAD801m (Public information from Sep 2024)
Share price
$3.29 CVAC
Company register number HRB 754041 (Stuttgart)
Tübingen Baden-Württemberg (HQ)
Financials
Estimates*
| EUR | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 48.9m | 103m | 67.4m | 53.8m | 177m | 72.4m | 107m |
| % growth | 181 % | 111 % | (35 %) | (20 %) | 229 % | (59 %) | 48 % |
| EBITDA | (110m) | (386m) | (223m) | (236m) | (14.1m) | (102m) | (71.2m) |
| % EBITDA margin | (225 %) | (375 %) | (331 %) | (439 %) | (8 %) | (140 %) | (67 %) |
| Profit | (130m) | (412m) | (249m) | (260m) | (126m) | (119m) | (102m) |
| % profit margin | (265 %) | (400 %) | (369 %) | (484 %) | (71 %) | (165 %) | (96 %) |
| EV / revenue | 213.2x | 47.2x | 9.0x | 9.2x | 2.3x | 3.2x | 3.2x |
| EV / EBITDA | -95.0x | -12.6x | -2.7x | -2.1x | -28.4x | -2.3x | -4.8x |
| R&D budget | 114m | 816m | 62.6m | 116m | - | - | - |
| R&D % of revenue | 233 % | 792 % | 93 % | 215 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
€2.7m | Series A | ||
€22.0m | Series B | ||
$34.9m | Series C | ||
€80.0m | Series D | ||
$52.0m | Series E | ||
€98.5m Valuation: €1.4b | Series F | ||
$29.5m | Series F | ||
€80.0m | Debt | ||
€300m | Growth Equity VC | ||
€75.0m | Debt | ||
$171m Valuation: $1.7b 88.7x EV/LTM Revenues -16.9x EV/LTM EBITDA | Late VC | ||
$126m Valuation: $1.7b 88.7x EV/LTM Revenues -16.9x EV/LTM EBITDA | Growth Equity VC | ||
| N/A | $213m Valuation: $2.8b 146.2x EV/LTM Revenues -27.8x EV/LTM EBITDA | IPO | |
€252m | Grant | ||
* | N/A | $450m | Post IPO Equity |
* | $250m | Post IPO Equity | |
| Total Funding | CAD1.7b | ||
Related Content
Recent News about CureVac
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by CureVac
Edit
ACQUISITION by CureVac Jun 2022